Article
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.
Hepatology (Baltimore, Md.) - 1 Jan 2015
Yoshida Eric M, Sulkowski Mark S, Gane Edward J, Herring Robert W, Ratziu Vlad, Ding Xiao, Wang Jing, Chuang Shu-Min, Ma Julie, McNally John, Stamm Luisa M, Brainard Diana M, Symonds William T, McHutchison John G, Beavers Kimberly L, Jacobson Ira M, Reddy K Rajender, Lawitz Eric
Abstract excerpt
UNLABELLED: Historically, clinical trials of regimens to treat chronic infection with hepatitis C virus (HCV) have used, as their primary efficacy endpoint, a sustained virological response (SVR)—defined as HCV RNA levels below a designated threshold of quantification—24 weeks after the end of treatment (SVR24). More recently, regulatory authorities have begun to accept SVR at 12 weeks post-treatment (SVR12) as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.